Welcome to our dedicated page for GERON SEC filings (Ticker: GERN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Geron Corporation filings document the regulatory record of a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing imetelstat for blood cancers. The company’s disclosures cover RYTELO product revenue, operating results, financial guidance, clinical-development updates, and risks tied to oncology drug commercialization and hematology studies.
Geron’s SEC filings also record proxy governance matters, director elections, board committee assignments, executive compensation, and stockholder voting materials. Form 8-K reports document material events including furnished earnings releases and investor materials, amendments to secured debt arrangements, Nasdaq-listed common stock information, workforce restructuring and exit-cost disclosures, and board or executive officer changes.
RA Capital Management, L.P. and related parties report a 9.99% beneficial stake in Geron Corporation as of June 30, 2026. Through RA Capital Healthcare Fund, L.P., they report beneficial ownership of 66,502,728 shares of common stock, including 42,809,751 shares held directly and Pre-Funded Warrants.
The Fund holds Pre-Funded Warrants exercisable for up to 29,053,145 additional shares, but a Beneficial Ownership Blocker prevents exercises that would push ownership above 9.99%. The 9.99% figure is calculated using 642,000,000 shares outstanding plus 23,692,977 shares issuable upon warrant exercise; EDGAR cover page percentages are rounded down to 9.9%. RA Capital, Peter Kolchinsky, and Rajeev Shah disclaim beneficial ownership except for Section 13(d) purposes.
State Street Corporation reported beneficial ownership of Geron Corp common stock on a Schedule 13G. State Street and its investment adviser subsidiaries collectively beneficially own 35,856,671 shares of Geron common stock, representing 5.6% of the outstanding class.
State Street reports 0 shares with sole voting or dispositive power. It has shared voting power over 34,097,965 shares and shared dispositive power over all 35,856,671 shares, reflecting holdings managed through its asset management entities, including SSGA Funds Management, Inc. and several State Street Global Advisors affiliates.
Geron Corporation reported second quarter 2026 results highlighted by continued growth of its telomerase inhibitor RYTELO. Net product revenue was $57.5 million for the quarter ended June 30, 2026, up from $49.0 million a year earlier. Total revenues were $57.5 million, while total costs and operating expenses rose to $70.0 million, largely due to higher non-cash inventory-related expenses. Geron recorded a net loss of $16.7 million, or $0.02 per share, compared with a net loss of $16.4 million, or $0.02 per share, in the prior-year quarter.
As of June 30, 2026, Geron held approximately $326.9 million in cash, cash equivalents, restricted cash and marketable securities, which it believes, together with anticipated RYTELO revenue, will fund operating requirements for the foreseeable future. For full-year 2026, the company reiterated guidance for RYTELO net product revenue of $220–$240 million and total operating expenses of $230–$240 million. Management noted that in the first half of 2026, RYTELO net revenue grew 24% and total operating expenses decreased 4% versus the same period in 2025, and emphasized strategic priorities including expanding RYTELO’s reach, advancing the Phase 3 IMpactMF trial in relapsed or refractory myelofibrosis, and pursuing additional innovation in blood cancer therapies.
Spiegel Robert J. reported acquisition or exercise transactions in this Form 4 filing.
Geron Corp director Robert J. Spiegel received 6,103 shares of common stock as compensation. The shares were granted on June 30, 2026 in lieu of cash payment for his quarterly board retainer and committee fees, based on the company’s closing share price of $1.28 that day.
Following this grant, Spiegel directly holds 205,810 Geron common shares. This is a routine, compensation-related stock award rather than an open-market purchase, so it mainly reflects how the company structures director pay, not an active trading decision.
Geron Corporation reported that stockholders approved an amendment and restatement of its 2018 Equity Incentive Plan, increasing the number of common shares issuable under the plan by 4,500,000 shares. The amendment had been previously adopted by the board of directors, subject to stockholder approval.
At the 2026 Annual Meeting, held virtually, stockholders elected director nominees including Susan M. Molineaux, Patricia S. Andrews and Constantine Chinoporos. Stockholders also approved additional proposals, including an advisory vote on executive compensation and the ratification of the independent registered public accounting firm, based on the vote totals disclosed.
Geron Corp director Robert J. Spiegel was granted a stock option for 220,000 shares of common stock. The option has an exercise price of $1.26 per share and expires on May 19, 2036.
The option will vest and become exercisable for 100% of the shares on the earlier of the company’s next annual stockholder meeting or the first anniversary of the grant date, as long as Spiegel remains in continuous service with Geron through that date.
GERON CORP director Elizabeth G. O'Farrell received a grant of stock options covering 220,000 shares of common stock. The options have an exercise price of $1.26 per share and expire on May 19, 2036. They vest 100% on the earlier of the next annual stockholder meeting or the first anniversary of the grant date, subject to her continuous service with the company. After this grant, she holds 220,000 options directly.
Geron Corp director Susan Molineaux received a compensation grant of stock options covering 220,000 shares of common stock at an exercise price of $1.26 per share. The option vests in full on the earlier of the company’s next annual stockholder meeting or the first anniversary of the grant date, contingent on her continuous service. Any unexercised portion expires on May 19, 2036. This is an equity award, not an open-market stock purchase or sale.
Geron Corp director John F. McDonald received a grant of 220,000 stock options to buy Geron common stock. The options have an exercise price of $1.26 per share and expire on May 19, 2036, providing long-term equity-based compensation.
According to the terms, the option will vest and become exercisable for all 220,000 underlying shares on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date, as long as McDonald continues to serve the company through that date. There were 220,000 derivative securities held after this grant, and the filing shows no open-market buying or selling.